Abstract
Neovascular age-related macular degeneration (nAMD), a leading cause of blindness in older adults, presents a challenging pathophysiology involving choroidal neovascularization (CNV) and retinal degeneration. Current treatments relying on intravitreal (IVT) administration of anti-angiogenic agents are costly and of moderate effectiveness. Metformin, the common anti-diabetic drug, has been associated with decreased odds of developing AMD. Studies have shown that metformin can mitigate cellular aging, neoangiogenesis, and inflammation across multiple diseases. This preclinical study assessed metformin’s impact on vessel growth using choroidal explants before exploring IVT metformin’s effects on laser-induced CNV and light-induced retinal degeneration in C57BL/6J and BALB/cJ mice, respectively. Metformin reduced new vessel growth in choroidal explants in a dose-dependent relationship. Following laser induction, IVT metformin suppressed CNV and decreased peripheral infiltration of IBA1+ macrophages/microglia. Furthermore, IVT metformin protected against retinal thinning in response to light-induced degeneration. IVT metformin downregulated genes in the choroid and retinal pigment epithelium which are associated with angiogenesis and inflammation, two key processes that drive nAMD progression. These findings underscore metformin’s capacity as an anti-angiogenic and neuroprotective agent, demonstrating this drug’s potential as an accessible option to help manage nAMD.
Funding Information
  • FORE-I Foundation (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • BrightFocus Foundation (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • Illinois Society for the Prevention of Blindness (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • The University of Chicago Women’s Board (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • Institute for Translational Medicine (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • Thome Memorial Foundation Award (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • Research to Prevent Blindness Sybil B. Harrington Career Development Award for Macular Degeneration (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • National Institutes of Health (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)
  • Northwestern University Center for Advanced Microscopy (M2018042, FP067271-01-PR, K08 EY030923, R01 EY034486, CCSG P30 CA060553)

This publication has 110 references indexed in Scilit: